NCT07763197
- Conditions
- Carcinoma, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, +15 more
- Locations
-
- Natera, Inc. Austin, Texas, United States
Clinical trial condition
High-Risk Non-Muscle Invasive Bladder Cancer
Explore clinical trials studying High-Risk Non-Muscle Invasive Bladder Cancer. Study availability and eligibility vary by location and protocol.
4 public trials
2 recruiting studies
High-Risk Non-Muscle Invasive Bladder Cancer trial results
NCT06378242
- Conditions
- High-Risk Non-Muscle Invasive Bladder Cancer
- Locations
-
- Sun Yat-sen Memorial Hospital,SunYat-sen University Guangzhou, Guangdong, China
- Tongji Hospital Wuhan, Hubei, China
- Hunan Cancer hospital Changsha, Hunan, China
- The first affiliated hospital with nanjing medical universtity Nanjing, Jiangsu, China
NCT07268339
- Conditions
- Carcinoma, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, +13 more
- Locations
-
- The Christie Manchester, United Kingdom
Active, not recruiting
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)
NCT03711032
- Conditions
- High-Risk Non-Muscle Invasive Bladder Cancer, Parkinson Disease 4, Autosomal Dominant Lewy Body
- Locations
-
- Alaska Urological Institute dba Alaska Clinical Research Center ( Site 1083) Anchorage, Alaska, United States
- Mayo Clinic in Arizona - Phoenix ( Site 1094) Phoenix, Arizona, United States
- Del Sol Research Management, LLC ( Site 1096) Tucson, Arizona, United States
- UCLA Hematology/Oncology - Westwood (Building 200 Suite 140)-Department of Urology/Institute of Uro ( Site 1052) Los Angeles, California, United States